A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study
一项关于口服3-氨基吡啶-2-甲醛硫代氨基脲(3-AP,NSC #663249)治疗晚期实体瘤的I期临床试验和药代动力学研究:加州癌症联盟研究
期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-011-1779-5
Chao, Joseph; Synold, Timothy W; Morgan, Robert J Jr; Kunos, Charles; Longmate, Jeff; Lenz, Heinz-Josef; Lim, Dean; Shibata, Stephen; Chung, Vincent; Stoller, Ronald G; Belani, Chandra P; Gandara, David R; McNamara, Mark; Gitlitz, Barbara J; Lau, Derick H; Ramalingam, Suresh S; Davies, Angela; Espinoza-Delgado, Igor; Newman, Edward M; Yen, Yun